

C4 vs Pathway Expression

	C4		IC(Δ)	P-val	FDR
	GROGER_EMT		0.900(0.003)	2.62e-06	7.33e-06
	SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE		0.898(0.003)	2.62e-06	7.33e-06
	TAUBE_EMT		0.894(0.004)	2.62e-06	7.33e-06
	ONDER_CDH1_TARGETS_2_UP		0.885(0.003)	2.62e-06	7.33e-06
	TAUBE_EMT_UP		0.884(0.003)	2.62e-06	7.33e-06
	TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL		0.880(0.004)	2.62e-06	7.33e-06
	ANASTASSIOU_CANCER_MESENCHYMAL_TRANSITION_SIGNATURE		0.877(0.003)	2.62e-06	7.33e-06
	ONDER_CDH1_TARGETS_2		0.876(0.004)	2.62e-06	7.33e-06
	BOQUEST_STEM_CELL		0.868(0.005)	2.62e-06	7.33e-06
	FARMER_BREAST_CANCER_CLUSTER_5		0.867(0.004)	2.62e-06	7.33e-06
	LIM_MAMMARY_STEM_CELL		0.866(0.004)	2.62e-06	7.33e-06
	WONG_ENDMETRIUM_CANCER_DN		0.861(0.004)	2.62e-06	7.33e-06
	GROGER_EMT_UP		0.859(0.004)	2.62e-06	7.33e-06
	TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP		0.858(0.004)	2.62e-06	7.33e-06
	SERVITJA_ISLET_HNF1A_TARGETS		0.857(0.004)	2.62e-06	7.33e-06
	CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_DN		0.854(0.004)	2.62e-06	7.33e-06
	JI_CARCINOGENESIS_BY_KRAS_AND_STK11_DN		0.854(0.003)	2.62e-06	7.33e-06
	BROWNE_HCMV_INFECTION_18HR_DN		0.853(0.005)	2.62e-06	7.33e-06
	VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY		0.853(0.005)	2.62e-06	7.33e-06
	HAEGERSTRAND_RESPONSE_TO_IMATINIB		0.847(0.006)	2.62e-06	7.33e-06
	BROWNE_HCMV_INFECTION_48HR		-0.823(0.007)	2.62e-06	1.49e-05
	BROWNE_HCMV_INFECTION_12HR		-0.824(0.006)	2.62e-06	1.49e-05
	CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP		-0.824(0.007)	2.62e-06	1.49e-05
	WAMUNYOKOLI_OVARIAN_CANCER_LMP		-0.826(0.006)	2.62e-06	1.49e-05
	URS_ADIPOCYTE_DIFFERENTIATION		-0.827(0.006)	2.62e-06	1.49e-05
	CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS		-0.828(0.006)	2.62e-06	1.49e-05
	BROWNE_HCMV_INFECTION_24HR		-0.830(0.006)	2.62e-06	1.49e-05
	WANG_CISPLATIN_RESPONSE_AND_XPC		-0.830(0.005)	2.62e-06	1.49e-05
	ZHU_CMV_24_HR		-0.832(0.005)	2.62e-06	1.49e-05
	MIKKELSEN_DEDIFFERENTIATED_STATE		-0.835(0.004)	2.62e-06	1.49e-05
	MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS		-0.837(0.004)	2.62e-06	1.49e-05
	HALLMARK_UV_RESPONSE		-0.837(0.005)	2.62e-06	1.49e-05
	CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL		-0.838(0.005)	2.62e-06	1.49e-05
	SWEET_LUNG_CANCER_KRAS		-0.842(0.005)	2.62e-06	1.49e-05
	WONG_ENDMETRIUM_CANCER		-0.846(0.005)	2.62e-06	1.49e-05
	BROWNE_HCMV_INFECTION_18HR		-0.847(0.005)	2.62e-06	1.49e-05
	CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL		-0.868(0.004)	2.62e-06	1.49e-05
	TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL		-0.881(0.004)	2.62e-06	1.49e-05
	LANDIS_ERBB2_BREAST_TUMORS_324		-0.888(0.004)	2.62e-06	1.49e-05
	LANDIS_BREAST_CANCER_PROGRESSION		-0.889(0.003)	2.62e-06	1.49e-05